Background Combined oral contraceptives (COC s) containing various progestogens could
be associated with differential risks for venous thromboembolism (VTE). Objective To …

Venous thromboembolic events (VTEs) represent a serious complication related to
hormonal contraception and hormone replacement therapy (HRT). Evidence on hormonal …

Objective To assess the risk of venous thromboembolism from use of combined oral
contraceptives according to progestogen type and oestrogen dose. Design National …

Purpose Defining a study population and creating an analytic dataset from longitudinal
healthcare databases involves many decisions. Our objective was to catalogue scientific …

Objective To assess the risk of venous thrombosis in current users of different types of
hormonal contraception, focusing on regimen, oestrogen dose, type of progestogen, and …

The incidence of venous thromboembolism exceeds 1 per 1000; over 200,000 new cases
occur in the United States annually. Of these, 30% die within 30 days; one-fifth suffer sudden …

Objective: To evaluate quantitatively articles that compared effects of second and third
generation oral contraceptives on risk of venous thrombosis. Design: Meta-analysis. Studies …

Objective To compare the risk of non-fatal venous thromboembolism in women receiving
oral contraceptives containing drospirenone with that in women receiving oral …

The objective of this study was to assess the influence of oral contraceptives (OCs) on the
risk of venous thromboembolism (VTE) in young women. A 5-year case-control study …

Objective To examine the risk of non-fatal idiopathic venous thromboembolism in current
users of a combined oral contraceptive containing drospirenone, relative to current users of …